Pharma Marketing Network
MARCH 8, 2025
Leverage first-party data to refine retargeting strategies while maintaining HIPAA compliance. FDA and HIPAA Compliance in PPC Fair balance requirements Ads must include benefits and risks equally. No unapproved drug claims All claims must be backed by clinical research and FDA-approved labeling.
Pharma Marketing Network
MARCH 31, 2025
As automation becomes smarter, ensuring HIPAA and GDPR compliance remains critical. Leveraging tools that enable real-time content approval and centralized tracking can prevent outdated messaging or off-label promotion. However, marketers must balance innovation with privacy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Marketing Network
JUNE 15, 2025
For starters, every email must comply with HIPAA, CAN-SPAM, and FDA regulations. Missteps in off-label promotion or data security can trigger legal and reputational risks. While email remains a powerful tool for engaging healthcare professionals and patients, it’s subject to unique constraints.
Pharma Marketing Network
MARCH 27, 2025
The emergence of HIPAA-compliant targeting technologies, HCP-specific segments, and improved analytics has made social platforms not just viable but essential for pharmaceutical marketing. While off-label promotion is still strictly regulated, unbranded awareness campaigns have found creative footing. It’s a strategic pillar.
Pharma Marketing Network
FEBRUARY 19, 2025
Challenges in Pharma Email Marketing Pharma brands face unique barriers that other industries dont , such as: Strict compliance regulations (FDA, GDPR, HIPAA) that limit messaging. Drug names and indications must align with FDA-approved labeling. Email fatigue among HCPs and patients , leading to low open rates.
Pharma Marketing Network
MAY 14, 2025
Compliance and Best Practices Adhere to Regulations: Pharma marketers must ensure that their programmatic campaigns comply with regulations such as HIPAA and FDA guidelines. This includes safeguarding patient data and avoiding off-label promotion. How can pharma marketers ensure compliance in programmatic campaigns?
Putting Patients First Blog
JULY 2, 2024
Enhance Dialogue-Based Engagement Clarify Required Disclosures Allow HIPAA Waivers if Feasible Clarify Speaker Selection Process Allow for Data Submissions After Sessions Increase Engagement. Off-label usage often emerges from real- world clinical practice and patient experiences, which might not be reflected in the guidelines.
Expert insights. Personalized for you.
59 
Let's personalize your content